228 related articles for article (PubMed ID: 17145815)
1. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.
Williams LH; Choong D; Johnson SA; Campbell IG
Clin Cancer Res; 2006 Dec; 12(23):6967-72. PubMed ID: 17145815
[TBL] [Abstract][Full Text] [Related]
2. Concomitant inactivation of p53 and Chk2 in breast cancer.
Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
4. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
Staalesen V; Falck J; Geisler S; Bartkova J; Børresen-Dale AL; Lukas J; Lillehaug JR; Bartek J; Lønning PE
Oncogene; 2004 Nov; 23(52):8535-44. PubMed ID: 15361853
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers.
Campbell IG; Phillips WA; Choong DY
Clin Cancer Res; 2006 Jun; 12(12):3713-5. PubMed ID: 16778097
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma.
Choy KW; Pang CP; Yu CB; Wong HL; Ng JS; Fan DS; Lo KW; Chai JT; Wang J; Fu W; Lam DS
Hum Mutat; 2002 Nov; 20(5):408. PubMed ID: 12402348
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of EP300 in colon, breast and ovarian carcinomas.
Bryan EJ; Jokubaitis VJ; Chamberlain NL; Baxter SW; Dawson E; Choong DY; Campbell IG
Int J Cancer; 2002 Nov; 102(2):137-41. PubMed ID: 12385008
[TBL] [Abstract][Full Text] [Related]
9. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
10. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer.
Liu MC; Choong DY; Hooi CS; Williams LH; Campbell IG
Cancer Lett; 2007 Mar; 247(1):91-7. PubMed ID: 16644110
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
13. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
14. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients.
Angelova SG; Krasteva ME; Gospodinova ZI; Georgieva EI
Neoplasma; 2012; 59(6):622-30. PubMed ID: 22862163
[TBL] [Abstract][Full Text] [Related]
15. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.
Szymanska-Pasternak J; Szymanska A; Medrek K; Imyanitov EN; Cybulski C; Gorski B; Magnowski P; Dziuba I; Gugala K; Debniak B; Gozdz S; Sokolenko AP; Krylova NY; Lobeiko OS; Narod SA; Lubinski J
Gynecol Oncol; 2006 Sep; 102(3):429-31. PubMed ID: 16828850
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
17. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer.
Bignell GR; Barfoot R; Seal S; Collins N; Warren W; Stratton MR
Cancer Res; 1998 Apr; 58(7):1384-6. PubMed ID: 9537235
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
[TBL] [Abstract][Full Text] [Related]
19. APC gene loss of heterozygosity, mutations, E1317Q, and I1307K germ-line variants in sporadic colon cancer in Croatia.
Kapitanović S; Cacev T; Radosević S; Spaventi S; Spaventi R; Pavelić K
Exp Mol Pathol; 2004 Dec; 77(3):193-200. PubMed ID: 15507235
[TBL] [Abstract][Full Text] [Related]
20. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
